Treatment of metastatic melanoma has undergone rapid advances with the development of immune checkpoint inhibitors. We report a case of bilateral choroidal effusions and exudative retinal detachments developing in a patient undergoing adjuvant combination ipilimumab and nivolumab for metastatic melanoma.
An African American man is his late 60s presented with a 3-week history of progressively worsening vision and seeing green spots bilaterally. He had an unremarkable ocular history but showed hyperopia with a refractive error of +5.00 diopters. His medical history was significant for stage IIIC metastatic melanoma. On presentation, he was participating in a clinical trial of adjuvant ipilimumab, 3 mg/kg, and nivolumab, 1 mg/kg, at 3-week intervals for treatment of previously resected metastatic melanoma. His first 2 cycles of immunotherapy were 5 weeks and 3 weeks prior to presentation. Because this is a single case report, no institutional review board approval was required. The patient provided written consent to have his case reported.
Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment. JAMA Ophthalmol. 2017;135(12):1455–1457. doi:10.1001/jamaophthalmol.2017.4872
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: